Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2025 | 2025 highlights in kidney cancer: TiNivo-2 and PDIGREE

Wenxin Xu, MD, Dana-Farber Cancer Institute, Boston, MA, provides an overview of recent and upcoming influential kidney cancer trials, including the Phase III TiNivo-2 trial (NCT04987203), which demonstrated the inferiority of tivozanib plus nivolumab over tivozanib alone, as well as the Phase III PDIGREE trial (NCT03793166) of nivolumab and ipilimumab with cabozantinib. Dr Xu additionally highlights updates in adjuvant pembrolizumab and triplet therapies incorporating lenvatinib or belzutifan. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.